LOGIN  |  REGISTER
C4 Therapeutics

Ardent Health Appoints Chief Development Officer to Lead Strategic Growth

May 19, 2025 | Last Trade: US$13.37 0.06 0.45

BRENTWOOD, Tenn. / May 19, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Chris Schoeplein as chief development officer.

In this new role, Schoeplein will lead development efforts across Ardent’s existing markets and support the organization’s expansion into new regions. He will be responsible for driving growth across inpatient and outpatient care settings through acquisitions, partnerships and joint ventures. Additionally, he will guide due diligence, market intelligence and integration planning to advance Ardent’s long-term growth strategy.

“We are excited to welcome Chris to Ardent at a pivotal time in our growth journey,” said Ardent Health President and CEO Marty Bonick. “His deep industry experience and strong track record of advising health systems will be instrumental as we pursue new opportunities to scale our consumer-centric platform and extend our unique joint venture model to benefit new partners and communities.”

Schoeplein joins Ardent from Kaufman Hall where he served as senior vice president in the firm’s mergers and acquisitions practice. With nearly two decades of healthcare strategy and development experience, he has built a successful track record helping health systems develop strategic partnerships that advance growth and enhance clinical and financial performance. Schoeplein is a graduate of Saint Louis University and a member of the Healthcare Financial Management Association.

About Ardent Health

Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. For more information, please visit ardenthealth.com.

Assertio

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page